BSF Enterprise PLC 3D Bio-Tissues Product Partnership Progress (5345U)

TIDMBSFA

RNS Number : 5345U

BSF Enterprise PLC

24 November 2023

24 November 2023

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues Product Partnership Progress

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues (3DBT), provides an update on the Company's partnership progress across several of 3DBT's product verticals.

Etsyl (TM) Commercial Update

3DBT is pleased to announce that it has entered into a proof-of-concept contractual agreement with one of the largest cosmetic companies in the world, which will test the suitability of the Company's proprietary lipopeptide product, Etsyl(TM), for use within its skin cream cosmetic solutions.

3DBT is harnessing the natural regenerative ability of human skin cells to drive rapid tissue regeneration and repair. Its Etsyl(TM) promotes cellular collagen production in human skin cells, with cosmetic and pharmacological applications as a bioactive ingredient in skincare formulations for the fabrication of native-like skin substitutes for clinical, cosmetic and industrial applications.

The cosmetic company which BSF is working with specialises in the research and development of bioactive ingredients for skin care which, with proven efficacy, can aid in anti-ageing, moisturising and acne control.

EIT Grant

In September 2023, 3D Bio-Tissues announced that it has been awarded a EUR612,000 grant from the European Institute of Innovation and Technology ("EIT Food") to upscale the production and sales of its proprietary serum-free media, City-Mix(TM). City-Mix(TM) is an animal-free cell growth agent for culturing skin, muscle and fat cells for use in cultivated meat and leather production.

Further to this, 3DBT is pleased to announce that it now has two new staff members in place to focus on securing additional procurement, manufacturing and distribution partnerships in the food-tech and biotech sectors, including Mr Adam Crosby, an operational manager with broad-level experience across multiple industries, and a successful track record in delivering multi-million-pound projects and facilitating growth. The Company has also hired an experienced Technical Sales Specialist to strengthen its sales team.

Book launch

Chief Executive of 3DBT, Professor Che Connon, has co-authored a book entitled Advances in Cultured Meat Technology, that explores the potential of cultured meat production in solving food security. Publication of the book is expected to further enhance Professor Connon, and the Company's international profile and reputation within the rapidly advancing cultured meat industry.

Che Connon, Chief Executive of 3DBT and Managing Director of BSF said: "We are delighted to be working with one of the world's largest cosmetic companies, which highlights the potential of our Etsyl product and the diverse applications of our technology. Furthermore, with an enlarged team in hand, we hope to secure further partnerships and sales for our various product offerings at an accelerated pace, and we look to the future with confidence."

   For further enquiries, please visit   www.bsfenterprise.com   or contact: 
 
 
 
   BSF Enterprise PLC                          Via SEC Newgate 
                                               below 
 Geoff Baker - Executive Director 
  Che Connon - CEO & Director 
 
 
   Shard Capital (Broker) 
 Damon Heath                                 0207 186 9000 
  Isabella Pierre                             0207 186 9927 
 
 
   SEC Newgate (Financial Communications) 
 Bob Huxford                                 020 3757 6882 
  Elisabeth Cowell                            [e-mail] 
  George Esmond 
 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people and successfully produced the UK's first high-quality lab-grown meat from its laboratory in Newcastle in 2023.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKNBQNBDBODB

(END) Dow Jones Newswires

November 24, 2023 02:00 ET (07:00 GMT)